metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)
mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population
mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant
versus osimertinib
	durvalumab plus osimertinib vs. osimertinib	1	2.60 [0.39; 17.16], 1 RCT, I2=0% inconclusive result	1.10 [0.22; 5.61], 1 RCT, I2=0% inconclusive result	-
mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative
mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive
versus Standard of Care (SoC)
	durvalumab alone vs. Standard of Care (SoC)	1	0.63 [0.42; 0.94], 1 RCT, I2=0% unassessable degree of certainty	0.71 [0.49; 1.03], 1 RCT, I2=0% inconclusive result	-
non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population
squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population